Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger? - Pharma News -BoardProspects

Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

Pharma News Mar 21 2019 BoardBlogs

After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Great Advice for Board Candidates (and Boards) By: Mark Rogers also categorized in BoardBlogs
- Actavis Chairman Joins Zoetis Board Under Deal With Activist Investor Ackman also published in Pharma News
- Everyone Gets Rated By Leigh Tucker also categorized in BoardBlogs
- AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises also published in Pharma News
- Nonprofit Governance: Why It Matters to Attend Board Meetings By Susan Hammond also categorized in BoardBlogs
- Responsibilities of a Nonprofit Board by Maria Peeler also categorized in BoardBlogs
- Is Your Board Meeting Location a Distraction? by Susan Hammond also categorized in BoardBlogs
- Are You Ready for an Advisory Board? Twelve Questions to Help You Decide By: Susan Hammond also categorized in BoardBlogs
- Who’s in charge here? By: Charles Whipple also categorized in BoardBlogs
- AstraZeneca Investors Press Exec-Comp Chair to Tie Pay to Pfizer Bid also published in Pharma News

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
Topics Mentioned
- CEO
- Management
- acquisition
- Investors
- risk
- Wall Street
- Credit Suisse
- ISS
- Starboard Value
- AstraZeneca
- Bristol-Myers Squibb
- Pascal Soriot
- Merger
- stake